BR112017004694A2 - composições farmacêuticas compreendendo alpelisibe - Google Patents

composições farmacêuticas compreendendo alpelisibe

Info

Publication number
BR112017004694A2
BR112017004694A2 BR112017004694A BR112017004694A BR112017004694A2 BR 112017004694 A2 BR112017004694 A2 BR 112017004694A2 BR 112017004694 A BR112017004694 A BR 112017004694A BR 112017004694 A BR112017004694 A BR 112017004694A BR 112017004694 A2 BR112017004694 A2 BR 112017004694A2
Authority
BR
Brazil
Prior art keywords
alpelisibe
pharmaceutical compositions
amide
pyrrolidin
benzamide
Prior art date
Application number
BR112017004694A
Other languages
English (en)
Inventor
Kochhar Charu
Stingelin Doris
Elbaz Frantz
Anna Maria Bock Michaela
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112017004694A2 publication Critical patent/BR112017004694A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção refere-se a comprimidos dispersáveis compreendendo o composto 1-({4-metil-5-[2-(2,2,2-triflúor-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) 2-amida de ácido (s)-pirrolidina-1,2-dicarboxílico ou um seu sal farmaceuticamente aceitável.
BR112017004694A 2014-10-03 2015-10-01 composições farmacêuticas compreendendo alpelisibe BR112017004694A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462059331P 2014-10-03 2014-10-03
PCT/IB2015/057523 WO2016051374A1 (en) 2014-10-03 2015-10-01 Pharmaceutical compositions comprising alpelisib

Publications (1)

Publication Number Publication Date
BR112017004694A2 true BR112017004694A2 (pt) 2017-12-05

Family

ID=54292871

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004694A BR112017004694A2 (pt) 2014-10-03 2015-10-01 composições farmacêuticas compreendendo alpelisibe

Country Status (14)

Country Link
US (3) US20170296523A1 (pt)
EP (2) EP3200772B1 (pt)
JP (1) JP6723229B2 (pt)
KR (2) KR102486126B1 (pt)
CN (2) CN107106497A (pt)
AU (1) AU2015326392B2 (pt)
BR (1) BR112017004694A2 (pt)
CA (1) CA2962714C (pt)
ES (1) ES2929554T3 (pt)
MX (1) MX2017004359A (pt)
PL (1) PL3200772T3 (pt)
PT (1) PT3200772T (pt)
RU (1) RU2690685C2 (pt)
WO (1) WO2016051374A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105919957A (zh) * 2016-06-13 2016-09-07 佛山市腾瑞医药科技有限公司 一种艾代拉利司分散片及其制备方法
AU2022232924A1 (en) * 2021-03-11 2023-07-06 Atossa Therapeutics, Inc. Endoxifen for treatment of ovarian cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
WO2011080502A2 (en) * 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
PE20140601A1 (es) * 2011-04-25 2014-05-24 Novartis Ag COMBINACION DE UN INHIBIDOR DE CINASA DE FOSFATIDIL-INOSITOL-3 (PI3K) Y UN INHIBIDOR DE mTOR
US20130004563A1 (en) * 2011-06-07 2013-01-03 Shah Syed Multiparticulate s-adenosylmethionine compositions and related methods
CA2839621A1 (en) * 2011-06-21 2012-12-27 Novartis Ag Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide
CA2866127A1 (en) * 2012-03-29 2013-10-03 Novartis Ag Pharmaceutical diagnostic
ES2694224T3 (es) * 2012-04-24 2018-12-19 Daiichi Sankyo Company, Limited Comprimido de desintegración oral y procedimiento para producir el mismo
WO2014007780A1 (en) * 2012-07-06 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally-disintegrating formulations of dexketoprofen
EP3251673A1 (en) * 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer

Also Published As

Publication number Publication date
JP6723229B2 (ja) 2020-07-15
CN107106497A (zh) 2017-08-29
PL3200772T3 (pl) 2022-12-19
KR20170056574A (ko) 2017-05-23
KR102598782B1 (ko) 2023-11-07
RU2690685C2 (ru) 2019-06-05
CN112957334B (zh) 2023-08-04
CA2962714C (en) 2023-09-19
EP3200772B1 (en) 2022-08-03
EP3200772A1 (en) 2017-08-09
KR102486126B1 (ko) 2023-01-09
CA2962714A1 (en) 2016-04-07
ES2929554T3 (es) 2022-11-30
KR20230008913A (ko) 2023-01-16
WO2016051374A1 (en) 2016-04-07
EP4169508A1 (en) 2023-04-26
RU2017114195A (ru) 2018-11-08
JP2017530143A (ja) 2017-10-12
CN112957334A (zh) 2021-06-15
MX2017004359A (es) 2017-06-23
US20220331305A1 (en) 2022-10-20
PT3200772T (pt) 2022-10-19
AU2015326392A1 (en) 2017-03-09
US20170296523A1 (en) 2017-10-19
US20190314353A1 (en) 2019-10-17
RU2017114195A3 (pt) 2018-11-16
AU2015326392B2 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
NZ721298A (en) Pharmaceutical compositions comprising azd9291
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
PH12018502307A1 (en) Aromatic sulfonamide derivatives
PH12017501079A1 (en) 1,3-thiazol-2-yl substituted benzamides
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
JP2015528502A5 (pt)
CR20130649A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
CO2018001383A2 (es) Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp”
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
EA201692433A1 (ru) Соединения ppar для применения при лечении фиброзных заболеваний
EP3995489A3 (en) Disulfide compounds for delivery of pharmaceutical agents
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
BR112018074985A2 (pt) composições antibacterianas
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
WO2016142821A3 (en) Compositions containing a thrombin inhibitor
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
CL2014002576A1 (es) Un metodo para tratar a un sujeto que tenga cancer que comprende administrar 1-(1(4-metil-5-(2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il)-tiazol-2-il)-amida) de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico en un sujeto que tenga una glutamina en la posicion 859 de la subunidad catalitica p110alfa de pi3k.
BR112017004694A2 (pt) composições farmacêuticas compreendendo alpelisibe
CO2018005064A2 (es) Bloqueador del canal de sodio
WO2016020408A3 (en) Compounds for preventing ototoxicity
BR112016015578A2 (pt) Inibidores de 17beta-hidroxiesteroide desidrogenases tipo 1 e tipo 2
TR201620309A2 (tr) Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
AR100175A1 (es) Inhibidores de autotaxina
EP3109232A4 (en) Optically active form of mepenzolate, and ameliorating agent for chronic obstructive pulmonary disease which contains same as active ingredient

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]